First Time Loading...
B

Bonus Biogroup Ltd
TASE:BONS

Watchlist Manager
Bonus Biogroup Ltd
TASE:BONS
Watchlist
Price: 16 ILS -1.84%
Updated: May 14, 2024

Intrinsic Value

BONS's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

Bonus Biogroup Ltd. is a biotechnology company engaging in the field of stem cells and tissue engineering. [ Read More ]

The intrinsic value of one BONS stock under the Base Case scenario is 1.87 ILS. Compared to the current market price of 16 ILS, Bonus Biogroup Ltd is Overvalued by 88%.

Key Points:
BONS Intrinsic Value
Base Case
1.87 ILS
Overvaluation 88%
Intrinsic Value
Price
B
Worst Case
Base Case
Best Case

Valuation Backtest
Bonus Biogroup Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling BONS stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Bonus Biogroup Ltd

Provide an overview of the primary business activities
of Bonus Biogroup Ltd.

What unique competitive advantages
does Bonus Biogroup Ltd hold over its rivals?

What risks and challenges
does Bonus Biogroup Ltd face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Bonus Biogroup Ltd.

Provide P/S
for Bonus Biogroup Ltd.

Provide P/E
for Bonus Biogroup Ltd.

Provide P/OCF
for Bonus Biogroup Ltd.

Provide P/FCFE
for Bonus Biogroup Ltd.

Provide P/B
for Bonus Biogroup Ltd.

Provide EV/S
for Bonus Biogroup Ltd.

Provide EV/GP
for Bonus Biogroup Ltd.

Provide EV/EBITDA
for Bonus Biogroup Ltd.

Provide EV/EBIT
for Bonus Biogroup Ltd.

Provide EV/OCF
for Bonus Biogroup Ltd.

Provide EV/FCFF
for Bonus Biogroup Ltd.

Provide EV/IC
for Bonus Biogroup Ltd.

Show me price targets
for Bonus Biogroup Ltd made by professional analysts.

Compare the intrinsic valuations
of Bonus Biogroup Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Bonus Biogroup Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Bonus Biogroup Ltd compared to its peers.

Compare the P/E ratios
of Bonus Biogroup Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Bonus Biogroup Ltd with its peers.

Analyze the financial leverage
of Bonus Biogroup Ltd compared to its main competitors.

Show all profitability ratios
for Bonus Biogroup Ltd.

Provide ROE
for Bonus Biogroup Ltd.

Provide ROA
for Bonus Biogroup Ltd.

Provide ROIC
for Bonus Biogroup Ltd.

Provide ROCE
for Bonus Biogroup Ltd.

Provide Gross Margin
for Bonus Biogroup Ltd.

Provide Operating Margin
for Bonus Biogroup Ltd.

Provide Net Margin
for Bonus Biogroup Ltd.

Provide FCF Margin
for Bonus Biogroup Ltd.

Show all solvency ratios
for Bonus Biogroup Ltd.

Provide D/E Ratio
for Bonus Biogroup Ltd.

Provide D/A Ratio
for Bonus Biogroup Ltd.

Provide Interest Coverage Ratio
for Bonus Biogroup Ltd.

Provide Altman Z-Score Ratio
for Bonus Biogroup Ltd.

Provide Quick Ratio
for Bonus Biogroup Ltd.

Provide Current Ratio
for Bonus Biogroup Ltd.

Provide Cash Ratio
for Bonus Biogroup Ltd.

What is the historical Revenue growth
over the last 5 years for Bonus Biogroup Ltd?

What is the historical Net Income growth
over the last 5 years for Bonus Biogroup Ltd?

What is the current Free Cash Flow
of Bonus Biogroup Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Bonus Biogroup Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Bonus Biogroup Ltd

Current Assets 33.2m
Cash & Short-Term Investments 32.8m
Receivables 370k
Non-Current Assets 19m
PP&E 18.6m
Intangibles 27k
Other Non-Current Assets 372k
Current Liabilities 5.4m
Accounts Payable 3.5m
Other Current Liabilities 1.9m
Non-Current Liabilities 10m
Long-Term Debt 10m
Efficiency

Earnings Waterfall
Bonus Biogroup Ltd

Revenue
0 ILS
Operating Expenses
-32.9m ILS
Operating Income
-32.9m ILS
Other Expenses
1.9m ILS
Net Income
-31m ILS

Free Cash Flow Analysis
Bonus Biogroup Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

BONS Profitability Score
Profitability Due Diligence

Bonus Biogroup Ltd's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

29/100
Profitability
Score

Bonus Biogroup Ltd's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

BONS Solvency Score
Solvency Due Diligence

Bonus Biogroup Ltd's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
Low D/E
63/100
Solvency
Score

Bonus Biogroup Ltd's solvency score is 63/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BONS Price Targets Summary
Bonus Biogroup Ltd

There are no price targets for BONS.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

BONS Price
Bonus Biogroup Ltd

1M 1M
-4%
6M 6M
+9%
1Y 1Y
+7%
3Y 3Y
-86%
5Y 5Y
-65%
10Y 10Y
-32%
Annual Price Range
16
52w Low
14.2
52w High
28.1
Price Metrics
Average Annual Return 20.58%
Standard Deviation of Annual Returns 102.19%
Max Drawdown -92%
Shares Statistics
Market Capitalization 195.7m ILS
Shares Outstanding 12 231 650
Percentage of Shares Shorted
N/A

BONS Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Bonus Biogroup Ltd

Country

Israel

Industry

Biotechnology

Market Cap

195.7m ILS

Dividend Yield

0%

Description

Bonus Biogroup Ltd. is a biotechnology company engaging in the field of stem cells and tissue engineering. The firm is developing cell therapy products based on autologous and allogeneic bone implants that will enable efficient bone transplant and provide cellular-based bone replacement prosthetics for repairing bone lesions. The company is targeting a worldwide market for the treatment of major disorders such as bone and cartilage related arthritis, osteoporosis, and various types of bones and joint trauma such as hip fractures and knee injuries, among others. On April 29, 2012, Bonus Bio Group Ltd fully acquired Bonus Therapeutic Ltd.

Contact

Haifa
Matam
+972732067100.0
http://www.bonusbiogroup.com

IPO

1993-08-20

Employees

52

Officers

Executive Chairman of the Board
Mr. Joseph Rauch M.B.A.
Founder, CEO, President & Director
Dr. Shai Meretzki Ph.D.
Chief Financial Officer
Mr. Yoni Livne CPA
Chief Operations Officer.
Dr. Dror Ben David Ph.D.
Head of Regulatory Affairs & VP of Clinical Affairs
Dr. Vered Kivity M.B.A., Ph.D.

See Also

Discover More
What is the Intrinsic Value of one BONS stock?

The intrinsic value of one BONS stock under the Base Case scenario is 1.87 ILS.

Is BONS stock undervalued or overvalued?

Compared to the current market price of 16 ILS, Bonus Biogroup Ltd is Overvalued by 88%.